Enhancing engagement for rare disease treatment
The Challenge
A pharmaceutical company with a promising treatment for a rare disease faced significant challenges. Despite the potential of their product, they lacked experience in collaborating with agencies and key opinion leaders (KOLs) to develop compelling content. The target patient population was not well-defined, and inconsistent messaging led to a shortage of diverse promotional materials. To overcome these obstacles and boost KOL engagement, the company turned to ClinicalMind.
The Solution
ClinicalMind partnered closely with the client to address these challenges, focusing on the following key initiatives:
Update Disease-State Awareness Program: Engaged a broad panel of KOLs to develop new slide content, fostering stronger relationships and a deeper understanding of the educational materials.
Standardize Terminology and Messaging: Ensured consistency across materials to align with target patient populations and updated disease-state branding guidelines.
Create a Case-Based Branded Roundtable Program: Designed to enhance interaction among healthcare professionals (HCPs) during promotional programs by:
Utilizing real patient cases previously presented at congresses by content development committee members.
Enhancing cases with new disease-state awareness information and key branded messages.
Providing multiple cases for flexibility.
Additionally, ClinicalMind developed succinct educational materials for the field force to maximize the value of office visits and complement peer-to-peer materials, including:
1-Page Leave-Behind on Mechanism of Disease: Simplified educational handouts for HCPs.
Branded Patient Case Studies: Abbreviated from the roundtable cases to provide clear, impactful information.
Unbranded 1-Page Patient Case Studies: Neutral educational materials to enhance understanding without brand bias.
The Results
ClinicalMind’s efforts had a profound impact:
Speaker Bureau Expansion: The number of speakers doubled.
Increased Program Utilization: Hundreds of new programs were launched using the newly developed disease-state content.
Positive Reception of Collateral Materials: The field force received the new materials enthusiastically.
Significant Revenue Growth: The client's revenue increased by 96% over the prior year.
The Vice President of Marketing and Training praised the collaboration: “This would not have been possible without the partnership and collective efforts from the ClinicalMind team. We had a great year, and we have high expectations for next year; without a team like ClinicalMind, this would have never been attainable.”